Skip to content
Screener

Dianthus Therapeutics DNTH Share Based Compensation Expense — Research And Development Expense

Other product segments

Personnel And Related Costs
$8.64M+47.7%
Other Costs
$1.49M+25.5%
Discovery Expenses
$1.36M+51.4%

Similar metrics at other companies

Innoviva, Inc. logo
INVAInternal Expenses — Research And Development Expense
$2.73M+127%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Helios Technologies logo
HLIOUnallocated Expenses — Research And Development Expense
$0—
Rein Therapeutics Inc. logo
RNTXEmployee Related Expenses — Research And Development Expense
$500K-19.6%
Rapport Therapeutics, Inc. logo
RAPPRAP219Program External Expenses — Research And Development Expense
$34.09M+252%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total claseprubart program-related expenses18,18916,591
Discovery expenses1,363900
Personnel and related costs8,6355,847
Stock-based compensation expense4,8482,475
Other costs1,4931,190
Total research and development expenses34,52827,003
General and administrative expenses:
Stock-based compensation expense5,7542,840

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's share based compensation expense — research and development expense?
Dianthus Therapeutics (DNTH) reported share based compensation expense — research and development expense of $4.85M in Q1 2026.
How has Dianthus Therapeutics's share based compensation expense — research and development expense changed year-over-year?
Dianthus Therapeutics's share based compensation expense — research and development expense increased by 95.9% year-over-year, from $2.48M to $4.85M.
What does share based compensation expense — research and development expense mean?
This metric represents the portion of total share-based compensation expense allocated specifically to research and development activities. It reflects the non-cash cost of equity-based awards granted to scientists, clinical researchers, and personnel directly involved in the development of the company's therapeutic pipeline. Monitoring this expense helps investors understand the true cost of human capital dedicated to innovation and clinical trial execution.

Ask your AI about Dianthus Therapeutics's share based compensation expense — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude